United States: Massachusetts Legislature Reaches Compromise On Opioid Legislation

On March 10, the Senate voted unanimously to pass a bill that offers long-awaited measures aimed at tackling the state's growing opioid abuse crisis. After House approval the previous day and seven weeks of conference committee negotiations, the bill is now on the governor's desk, and is poised to become law. It includes restrictions on first-time opioid prescriptions, student and emergency room patient screenings, and a measure allowing partial-fill prescriptions. Governor Baker has long prioritized opioid legislation, and had been pushing for an agreement before the legislature is overwhelmed with the budget this spring.

The issue of opioid abuse is likely considered the number-one priority this year for the House, Senate and Governor's office. While it is likely that every state in the U.S. has significant overdose deaths, the perception, and perhaps the reality, is that Massachusetts has an abnormally high number of overdose cases and deaths – a recent documentary on HBO that focused on heroin on Cape Cod was heralded by the governor as a wake-up call to Massachusetts, and the desire and need to do something legislatively was clear.

While the House and Senate took different approaches on some of the key provisions – like the number of hours that physicians can hold an overdose patient – there were no significant sticking points. The political reality is that this bill was destined to pass, and the likelihood is high that the governor will sign the bill outright. However, he has 10 days to review the bill. During this time, he could veto or return the bill "with an amendment," meaning he would strike out the text and insert his own version of the entire bill.

Seven-Day and Partial-fill Opioid Prescriptions

The bill would impose a seven-day limit on doctors' prescriptions to first-time opioid users. Governor Baker had initially proposed a three-day limit, but the Massachusetts Medical Society and other groups successfully argued that doctors should have more freedom to prescribe medications to their patients as they saw fit.

Patients would also be able to partially fill their opioid prescriptions, asking pharmacists for fewer than the number of pills prescribed. Doctors would have to inform patients of this option.

Drug Stewardship

Pharmaceutical companies that manufacture opioids would be required to participate in a "drug stewardship" program to facilitate the disposal of unwanted opioids. Either individually or in groups labeled "stewardship organizations," these companies would be tasked with creating a program to collect, secure, transport, and dispose of the drugs. The Department of Public Health would approve proposals for these programs and set the costs of participation. The bill lists drop-off day events, mail-back initiatives, or at-home disposal methods as acceptable options for drug takeback programs. Drug companies would be required to submit annual reports on their initiatives, and any company deemed noncompliant with the measure could be fined. This program has a sunset provision, expiring on December 31, 2021.

Arguably, the final language differs substantially from the stewardship program as proposed in the Senate's version of the bill. The Senate proposed to specify that the costs of the program must relate to a manufacturer's "total sales" and such assessments shall be based in part on the "total volume" of pills sold based on a per pill formula.

Other changes in the conference committee version include removing language that required the takeback programs to be accessible in all parts of the state, and that detailed what themes the public awareness campaigns must address.

The conference committee language states that the Department of Public Health may create an alternative method of complying with the stewardship program by participating in a program in concert with industry groups such as the Massachusetts Biotechnology Council. This new proposal allows for "contributions by manufacturers" to the Substance Abuse Services Fund, but does not specify how the contributions are to be calculated.

School and Hospital Screenings

Schools and emergency rooms would be affected by new screening requirements set forth in the legislation. Schools would have to screen students for signs of addiction or substance abuse, though students and parents could opt out of these sessions. One proposed screening method is called "Screening, Brief Intervention, and Referral to Treatment," or SBIRT, though schools could also select an alternative program. The Department of Elementary and Secondary Education would choose two grades in which students would be screened.

Doctors would also have 24 hours to evaluate anyone who arrives at an acute care hospital with signs of an overdose, though this screening too is voluntary. This measure takes the place of Governor Baker's controversial proposal to authorize hospitals to hold addicts against their will for 72 hours, in order to allow doctors to evaluate these patients and decide whether to seek longer commitments. This proposal received significant pushback from critics who raised civil liberties concerns and said there are not have enough treatment beds, so it was replaced with the 24-hour screening requirement.

Training for Medical Professionals

All medical school students would receive training in substance abuse disorders and alternative approaches to pain management – a measure building on medical and dental schools' initiatives earlier this year to incorporate addiction education into their curricula.

Prescription Monitoring Program Database

The bill requires doctors to check the state's prescription monitoring program database before writing a prescription for a Schedule 2 or Schedule 3 narcotic. They would also have to speak with patients about the danger of opioid abuse. Patients could also note in their electronic health records that they do not want to receive any opioids.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Similar Articles
Relevancy Powered by MondaqAI
In association with
Related Topics
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions